Astrazeneca Regulatory News (AZN)

6 June 2017 07:00 BST

ASTRAZENECA PRICES A $2BN BOND ISSUE

AstraZeneca PLC announces that, on 5 June 2017, it priced a three tranche Global bond offering totalling $2bn. The offering is expected to close on 12 June 2017, subject to customary closing conditions. AstraZeneca expects to use the net proceeds of the issue for general corporate purposes which may include the refinancing of existing indebtedness. The transaction, which is a global offering registered with the US Securities and Exchange Commission (SEC), consists of the following three tranches: 

· $1bn of 5 year fixed rate notes with a coupon of 2.375%;

· $0.75bn of 10 year fixed rate notes with a coupon of 3.125%; and

· $0.25bn of 5 year floating rate notes.

Barclays, BofA Merrill Lynch, HSBC and Morgan Stanley acted as joint-bookrunning managers on the transaction. The notes will be issued under AstraZeneca's effective shelf registration statement on Form F-3, which AstraZeneca filed with the SEC on 22 November 2016. The offering is being made solely by means of the prospectus contained within that shelf registration statement, along with a prospectus supplement forming part of the effective registration statement, which investors should read.

A copy of the prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting Barclays Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847 or by email at barclaysprospectus@broadridge.com; HSBC Securities (USA) Inc., 452 Fifth Avenue, New York, NY 10018, Attention: Transaction Management Group, by telephone at 1-866-811-8049; Merrill Lynch, Pierce, Fenner & Smith Incorporated, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attention: Prospectus Department, by telephone at 1-800-294-1322 or by email at dg.prospectus_requests@baml.com; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649 or by email at prospectus@morganstanley.com. You may also download these documents for free by visiting EDGAR on the SEC website at www.sec.gov.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The bond issuance does not impact the Company's financial guidance for 2017.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Cautionary Statements Regarding Forward-Looking Statements

This announcement contains certain forward-looking statements with respect to the operations, performance and financial condition of AstraZeneca. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this announcement and AstraZeneca undertakes no obligation to update these forward-looking statements.

Adrian Kemp

Company Secretary, AstraZeneca PLC